食管癌患者外周血调节性T细胞亚群格局变化及其临床意义  

Regulatory T Cell Subset Alteration in the Peripheral Blood of Patients with Esophageal Cancer and Its Clinical Significance

作　　者：赵强[1] 张毅敏[1] 杨迅[1] 陈奇勋[1] 毛伟敏[1] 

机构地区：[1]浙江省肿瘤医院,浙江省胸部肿瘤(肺,食管)诊治技术研究重点实验室,浙江杭州310022

出　　处：《肿瘤学杂志》2013年第4期285-288,共4页Journal of Chinese Oncology

摘　　要：[目的]分析食管癌患者外周血CD4+CD25+CD127-调节性T细胞(Treg)占CD4+T细胞的比例变化。[方法]采用流式细胞仪检测104例食管癌患者和68例健康及良性疾病对照者外周血中CD4+CD25+CD127-Treg占CD4+T细胞的比例,分析其与临床分期、淋巴结转移及外膜受侵的关系。[结果]食管癌患者与对照组的外周血CD4+CD25+CD127-Treg占CD4+T细胞比例分别为(5.19%±1.82%)和(4.56%±1.16%),两组比较差异有统计学意义(t=2.544,P=0.012)。Ⅱa期CD4+CD25+CD127-Treg细胞比例分别与Ⅱb期和Ⅲa期比较,差异均有统计学意义(P<0.01);不同年龄、淋巴结及外膜受侵状况患者的外周血CD4+CD25+CD127-Treg细胞比例变化比较无统计学差异(P>0.05)。[结论]食管癌患者外周血CD4+CD25+CD127-Treg占CD4+T细胞的比例明显升高,且分期高患者升高更为明显,提示可能与食管癌免疫逃逸和免疫耐受有关。[Purpose] To investigate proportion alteration of CD4＋CD25＋CD127- regulatory T cells in CD4＋ T cells in peripheral blood of the patients with esophageal cancer. [Methodsl The percentage of CD4＋CD25＋CD127- regulatory T cells in CD4＋ T cells in peripheral blood of 104 patients with esophageal cancer and 68 healthy and benign disease controls was detected by flow cytometry, and its relation with clinical stage,lymphatic metastasis and serosa invasion was analyzed. [Results] The percentage of CD4＋CD25＋CD127- regulatory T cells in CD4~ T cells in peripheral blood of patients with esophageal cancer and of control group was （5.19%_＋1.82%） and （4.56%＋ 1.16%） respectively, with significant difference between them （t=-2.544, P=0.O 12）. The percentage of CD4＋CD25＋CDI27- regulatory T ceils in stage II a was significantly different with that in stage l]b or stage Ilia （P〈0.01）.But no significant difference was found with that in age,lymph node metastasis and serosa invasion status（P〉0.05）.[Conclusion] The increasing per- centage of CD4＋CD25＋CD127- regulatory T cells in the patients of esophageal cancer and much higher in advanced stages. It might relate to immunological escape and immunological tolerance of esophageal cancer.

关 键 词：食管肿瘤 CD4+CD25+CD127-调节性T细胞 外周血 流式细胞术 

分 类 号：R392.4[医药卫生—免疫学]